This review critically examines the evolution of treatment strategies for HER2-positive mBC, focusing on first-line treatment selection, maintenance, CNS management, post-T-DXd sequencing, long responders, mechanisms of resistance and biomarker development.
M. Palleschi, A. Viansone, Filippo Merloni et al.· Cancer Treatment Reviews· 0 citations
Conclusively, single‐CTC analysis enables comprehensive characterization of the PI3K/AKT/PTEN pathway, revealing molecular heterogeneity and capturing events not detectable by tumor tissue or ctDNA.
T. Rossi, M. Palleschi, C. Gianni et al.· Cancer Science· 0 citations
While advanced-stage BC often presents an immunosuppressive tumor microenvironment that hinders vaccine efficacy, early-stage disease offers a more favorable immunological milieu for inducing robust and durable T-cell responses.
A. Caltavituro, C. Martinelli, M. Palleschi et al.· Journal of Experimental &...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.